These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 8042263)

  • 21. [A study on the cause of urolithiasis of the upper urinary tract--clinical study of risk factors in the formation of stones in the upper urinary tract].
    Nonomura M; Kawamura J; Ueda M; Okada Y; Takeuchi H; Yoshida O
    Hinyokika Kiyo; 1986 Mar; 32(3):311-25. PubMed ID: 3728237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic abnormalities associated with calyceal diverticular stones.
    Auge BK; Maloney ME; Mathias BJ; Pietrow PK; Preminger GM
    BJU Int; 2006 May; 97(5):1053-6. PubMed ID: 16643491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and metabolic evaluation of Korean patients with urolithiasis.
    Park KJ; Jeon SS; Han DH; Lee SY
    Scand J Clin Lab Invest; 2011 Oct; 71(6):481-5. PubMed ID: 21714706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term effects of potassium citrate therapy on the formation of new stones in groups of recurrent stone formers with hypocitraturia.
    Whalley NA; Meyers AM; Martins M; Margolius LP
    Br J Urol; 1996 Jul; 78(1):10-4. PubMed ID: 8795392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Twenty-four-hour urine chemistries and the risk of kidney stones among women and men.
    Curhan GC; Willett WC; Speizer FE; Stampfer MJ
    Kidney Int; 2001 Jun; 59(6):2290-8. PubMed ID: 11380833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Urinary citrate excretion in children with calcium urolithiasis].
    Sikora P; Bieniaś B; Majewski M; Borzecka H; Wawrzyszuk M; Zajaczkowska M
    Przegl Lek; 2006; 63 Suppl 3():134-6. PubMed ID: 16898511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Agglomeration inhibition reflected stone-forming activity during long-term potassium citrate therapy in calcium stone formers.
    Fuselier HA; Moore K; Lindberg J; Husserl FE; Cole FE; Kok DJ; Whitehead D; Galliano DJ; Erwin DT
    Urology; 1998 Dec; 52(6):988-94. PubMed ID: 9836542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insulin resistance and low urinary citrate excretion in calcium stone formers.
    Cupisti A; Meola M; D'Alessandro C; Bernabini G; Pasquali E; Carpi A; Barsotti G
    Biomed Pharmacother; 2007 Jan; 61(1):86-90. PubMed ID: 17184967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Urinary citrate determination in normal persons and in patients with recurrent urinary calculi].
    Noronha Ide L; Andriolo A; Wroclawski E; Chade J; Lucon AM; Arap e Emil S; Sabbaga E
    Rev Hosp Clin Fac Med Sao Paulo; 1992; 47(1):12-8. PubMed ID: 1307398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The risk of recurrent urolithiasis in children is dependent on urinary calcium and citrate.
    DeFoor WR; Jackson E; Minevich E; Caillat A; Reddy P; Sheldon C; Asplin J
    Urology; 2010 Jul; 76(1):242-5. PubMed ID: 20110113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute acid load in recurrent oxalate stone formers.
    Knispel HH; Fitzner R; Kaiser M; Butz M
    Urol Int; 1988; 43(2):93-6. PubMed ID: 3388639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical studies on recurrence of urolithiasis. (2) Hypercalciuria and recurrence of urolithiasis].
    Murayama T; Taguchi H
    Hinyokika Kiyo; 1987 Nov; 33(11):1766-71. PubMed ID: 3445858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The characteristics of the stone and urine composition in Chinese stone formers: primary report of a single-center results.
    Wu W; Yang D; Tiselius HG; Ou L; Liang Y; Zhu H; Li S; Zeng G
    Urology; 2014 Apr; 83(4):732-7. PubMed ID: 24485999
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urinary citrate, bone resorption and intestinal alkali absorption in stone formers with fasting hypercalciuria.
    Messa P; Mioni G; Paganin L; Cruciatti A; Greco PL; Turrin D
    Scanning Microsc; 1994; 8(3):531-8; discussion 538-9. PubMed ID: 7747155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines.
    Skolarikos A; Straub M; Knoll T; Sarica K; Seitz C; Petřík A; Türk C
    Eur Urol; 2015 Apr; 67(4):750-63. PubMed ID: 25454613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Twenty-four-hour urine constituents in stone formers: a study from the northeast part of Peninsular Malaysia.
    Hussein NS; Sadiq SM; Kamaliah MD; Norakmal AW; Gohar MN
    Saudi J Kidney Dis Transpl; 2013 May; 24(3):630-7. PubMed ID: 23640651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Urinary citrate excretion in patients with urolithiasis and normal subjects.
    Nikkilä M; Koivula T; Jokela H
    Eur Urol; 1989; 16(5):382-5. PubMed ID: 2776809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urolithiasis in geriatric patients.
    Usui Y; Matsuzaki S; Matsushita K; Shima M
    Tokai J Exp Clin Med; 2003 Jul; 28(2):81-7. PubMed ID: 14714833
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of comprehensive and limited metabolic evaluations in the treatment of patients with recurrent calcium urolithiasis.
    Yagisawa T; Chandhoke PS; Fan J
    J Urol; 1999 May; 161(5):1449-52. PubMed ID: 10210370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Physiological and physiochemical correction and prevention of calcium stone formation by potassium citrate therapy.
    Pak CY; Sakhaee K; Fuller CJ
    Trans Assoc Am Physicians; 1983; 96():294-305. PubMed ID: 6679957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.